auto_awesome_motion View all 4 versions
organization

EORTC

European Organisation for Research and Treatment of Cancer
Country: Belgium
13 Projects, page 1 of 3
  • Open Access mandate for Publications
    Funder: EC Project Code: 635342
    Overall Budget: 4,948,740 EURFunder Contribution: 4,948,740 EUR
    Partners: L'AZIENDA SOCIO SANITARIA TERRITORIALE (ASST) GRANDE OSPEDALE METROPOLITANO NIGUARDA, KUL, UNITO, UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI, FIHCUV, AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA, EORTC, ICO, NKI ALV, FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE...

    Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different. We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assays identify gene expression profiles with distinct prognosis and drug response phenotypes (CMS4/c-type, BRAF mutant-like, and MSI-like). Our overall objective is to develop targeted therapies more effective than the current therapies that do not take advantage of molecular classification of the disease to select patients for therapy. We therefore propose to perform 3 two-stage single arm multi-centre open-label phase II studies based on solid preclinical evidence and a sound scientific rationale for these subgroups of CRC patients: 1) combination of chemotherapy and a TGF-βR inhibitor (LY2157299) in patients presenting a C-type signature; 2) vinorelbine in patients with a BRAFm-like signature; and 3) an immunotherapeutic anti-PD-L1 drug (MPDL3280A) in combination with bevacizumab in patients with a MSI-like signature. The primary objectives of these studies are to determine the clinical efficacy (progression-free survival as primary endpoint), safety and tolerability of the experimental treatments in these molecularly selected populations. Mutation analysis at the beginning of treatment and monitoring by liquid biopsies might reveal further biomarkers that predict response in retrospective analysis. The project outcomes may have a significant impact in CRC patients with poor-risk prognosis worldwide as 40-50% of them present gene expression profiles matching one of the 3 approaches. Around 40,000 European CRC patients may potentially benefit from the results. Also, these may be translated to other cancer types with equivalent gene expression patterns/deregulated signalling pathways.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101057482
    Overall Budget: 7,292,900 EURFunder Contribution: 7,235,020 EUR
    Partners: FFUND BV, INT, UM, FUNDATIA YOUTH CANCER EUROPE, CLB, STICHTING INTEGRAAL KANKERCENTRUM NEDERLAND, ECCO, Maria Sklodowska-Curie National Research Institute of Oncology, Institut Gustave Roussy, EORTC...

    STRONG-AYA is a new, interdisciplinary, multi-stakeholder European network to improve healthcare services, research and outcomes for Adolescents and Young Adults (AYA) with cancer, defined as individuals aged 15-39 years at cancer diagnosis. AYAs with cancer form a unique group; they face age-specific issues (e.g. infertility, unemployment, financial problems) and decreased quality of life due to cancer and its treatment. Unlike dedicated healthcare and trials for pediatric cancer patients, AYA-specific healthcare services are scarce and vary across Europe. AYAs who are at the core of society and economy need access to age-adjusted and high-quality healthcare. AYA-care and research will benefit from collection and pooling of patient-centered data and collaboration among all stakeholders: patients, healthcare professionals, scientists, and policymakers. Our consortium of clinical and scientific leaders in AYA-care, data science and registries, European Cancer Organisation, Youth Cancer Europe and EORTC will build on previous initiatives and EU grants. Within STRONG-AYA we will set up a value-based healthcare research ecosystem to develop data-driven, interactive policy and visualization tools that bring, in co-creation with all stakeholders including patients, novel insights into AYA healthcare. The project objectives, include: 1) Development of a Core Outcome Set (COS) for AYAs with cancer; 2) Implementation of the COS in 5 national healthcare systems (FR, IT, NL, UK, PL) and establish national infrastructures for outcome data management and clinical decision-making and a pan-European ecosystem that also welcomes future European countries; 3) Disseminate outcomes and facilitate interactions between national and pan-European stakeholders to develop data-driven analysis tools to process and present relevant outcomes, establish feedback loops for AYA cancer patients and the healthcare systems, and improve the reporting and assessment of outputs towards policy-makers.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 825162
    Overall Budget: 9,640,780 EURFunder Contribution: 9,640,780 EUR
    Partners: University of York, Utrecht University, Medical University of Sofia, SYREON, UB, UPM, NICE, EORTC, Zorginstituut Nederland, University of Oulu...

    HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and real-time decision-making for integrated healthcare throughout Europe. HTx will focus on therapeutic areas with high unmet need for which HTA information has to be provided on complex and personalised combinations of health technologies. Based on a select number of relevant case studies, HTx will enhance methods for integrating evidence from RCTs and real-world data (RWD). HTx will also augment statistical and econometric methods for generating robust estimates of effectiveness and cost-effectiveness in order to support relevant HTA decision-making for these complex and personalised combinations of health technologies. HTx will also contribute to improving methods to support personalised treatment advice fitted for sharing with patients and their physicians. This includes the development of statistical and econometric approaches and artificial intelligence/machine learning methods for forecasting treatment effects in specific groups of patients. Simultaneously, in close collaboration with the European Network for HTA (EUnetHTA), HTx will improve synergies between regulatory agencies, HTA bodies and clinical guideline developers. This will include the translation of HTx methods into already existing European guidelines, most prominently those developed by EUnetHTA. HTx will also support initial efforts to discuss reimbursement and funding models that facilitate controlled access to and the pricing of these complex health technologies. Finally, we will evaluate the transferability of HTx results into all EU Member Countries especially in Central and Eastern European (CEE) Countries and promote the dissemination of HTx results to the different European stakeholders with a special focus on the patient community.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101058620
    Overall Budget: 14,866,400 EURFunder Contribution: 14,866,400 EUR
    Partners: UMINHO, TTOP, EURO-BIOIMAGING ERIC, INSTRUCT-ERIC, FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE, ECRIN, UNITO, ARTTIC INNOVATION GMBH, EMBRC-ERIC, EORTC...

    canSERVs mission is to make cutting-edge and customised research services available to the cancer research community EU wide, enable innovative R&D projects and foster precision medicine for patients benefit across Europe. By connecting, coordinating, and aligning existing oncology and complimentary research infrastructures (RIs) and providing services in a synergistic way transnationally, canSERV will capitalise on the critical mass of experts and cutting-edge services offered by canSERVs RIs and their extended network. canSERV brings together world-class European life science RIs (BBMRI, EURO-BIOIMAGING, ELIXIR, EU-IBISBA, EuroPDX, EU-OPENSCREEN, INSTRUCT, EATRIS, INFRAFRONTIER, EMBRC, ECRIN, EATRIS, MIRRI, ARIE, CCE, EORTC and IARC) that collectively not only covers all aspects along the development pipeline for oncology, but is also capable of interconnecting these technologies providing users a guidance for navigating them through the entire translational value chain. The patient organisation ECPC will bring the patient?s perspective, while the two SMEs, ARTTIC and ttopstart, will provide valuable input regarding stakeholder engagement, and project management activities. A common access management system (CAMS) will be developed based on mature solutions from INSTRUCT and BBMRI. The CAMS will provide a method for selection of services, construction and submission of research proposals, multi-step review of research proposals, and tracking of the access process from approval through delivery to conclusion. Through a united user-intuitive transnational access where a united catalogue of oncology services will be offered, our users will have access to a comprehensive service portfolio. As our ambition is to scale up canSERV to a pan-European collaboration of RIs for accelerating the development and implementation of solutions for the cancer patient community, the sustainability of this network beyond the end of the project will also be addressed.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 101096362
    Overall Budget: 10,607,300 EURFunder Contribution: 10,607,300 EUR
    Partners: Oslo University Hospital, FAVO, ECCO, MUI, FUNDACIO INSTITUT HOSPITAL DEL MAR D INVESTIGACIONS MEDIQUES, Institute Curie, UNICANCER, ISTITUTO EUROPEO DI ONCOLOGIA SRL, GERMAN CANCER RESEARCH CENTER, OECI...

    EUonQoL aims to develop, pilot and validate the EUonQoL-Kit, a patient-driven, unified system for the assessment of quality of life (QoL) based on evaluations and preferences of cancer patients and survivors. The EUonQoL-Kit will be developed from a patient perspective, administered digitally, available in the EU27 and Associated countries languages, and applicable in future, periodic surveys to contribute to the EU’s mission on cancer. At the core of the EUonQoL there is the adoption of a multistakeholder, co-design methodology, engaging patient representatives, healthcare professionals, administrators, policymakers, and citizens in all project related activities. Existing QoL tools will be reviewed, scoping all relevant sources. This review will be used in the context of the codesign consensus with stakeholders’ and patients’ preferences to identify gaps and establish all QoL dimensions that are relevant from the perspectives of patients, clinicians, and society. A multidisciplinary researcher panel, composed by the most talented experts, will develop the EUonQoL-Kit that will be validated in a pilot survey using digital data collection within month 24 of the project. A total of 4,000 cancer patients and survivors will be enrolled through a network of EU cancer centers. An analysis of factors potentially impacting on cancer patients and survivors QoL, will also be performed. Implementation and exploitation strategies, as well as the linkage with other Cancer Mission projects and actions will be explored to develop future periodic surveys. EUonQoL is composed by research institutions, cancer centers, as well as scientific, professional, and patient representative organizations involved in cancer research, all with extensive experience and robust scientific background in the development of self-report QoL measures.This partnership fuels the ambition of EUonQoL to translate QoL information into future changes in cancer care policy and clinical practice.